PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort studyResearch in context

Summary: Background: Immunotherapy with atezolizumab and durvalumab has significantly advanced the treatment of extended-stage small cell lung cancer (esSCLC). We aimed at studying the real-world use and comparative effectiveness and safety of these treatments. Methods: We utilised the French Natio...

Full description

Bibliographic Details

Published in:	The Lancet Regional Health. Europe
Main Authors:	Hugo Jourdain, Nicolas Albin, Adrien Monard, David Desplas, Mahmoud Zureik, Nadia Haddy
Format:	Article
Language:	English
Published:	Elsevier 2025-12-01
Subjects:	Extended-stage small cell lung cancer Immunotherapy Atezolizumab Durvalumab Epidemiology French National Health Data System (SNDS)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666776225002765